Rowan University and Sentrimed, a clinical-stage biopharmaceutical company focused on developing safer, orally dosed oncology therapies, today announced results from a National Cancer Institute (NCI) ...

Significant regulatory advances for lead candidate EB613 streamline Phase 3 clinical development and reduce regulatory hurdles. These 10 stocks could mint the next wave of millionaires › Entera Bio ...

Key Points GAAP earnings per share of $(1.99) for Q2 2025 missed analyst estimates by $0.07. Net loss attributable to common stockholders (GAAP) narrowed to $5.7 million for Q2 2025, down from $7.4 ...

Clinical trial updates in cancer care include a remote study in small cell lung cancer and new findings in ovarian, solid ...

Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for ...

Q2 2025 Management View CEO Richard A. Miller stated the company's main focus remains the development of soquelitinib for atopic dermatitis, highlighting "an oral medication featuring a novel ...

Q1 2026 Management View CEO Shawn K. Singh highlighted progress on the company's late-stage neuroscience pipeline, emphasizing the advancement of intranasal fasedienol through Phase III development ...